Weight-loss drugs’ challenge to pharma’s safety infrastructure

For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity… Read More

27 May 2026 #Exclusive Content #Opinion